Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Larkspur Biosciences announced the first participant has been dosed in the Phase 1 clinical study of its lead candidate, LRK-4189, in healthy volunteers.
-
Larkspur Biosciences Announces Discovery of LRK-4189, 1st-in-Class Degrader of Lipid Kinase PIP4K2C, for Treatment of MSS CRC at ACS Fall 2025 Meeting
-
Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024
-
WATERTOWN, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that stops immune evasion from where it starts in the tumor, announced...
-
WATERTOWN, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a biotechnology company building precision therapies to outsmart cancer, announced that data supporting development of a...
-
Research foundational to Larkspur’s newly disclosed TIM-1 program published by founder Vijay K. Kuchroo in Nature WATERTOWN, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences revealed...
-
WATERTOWN, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a biotechnology company building the next precision immunotherapies to outsmart cancer, announced that they will be...
-
Addressing the Key Bottlenecks in the Tumor Microenvironment That Allow a Tumor to Subvert the Immune System Financing Co-led by Polaris Innovation Fund, 3E Bioventures Capital, and Takeda...